Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioPorto A/S (BIOPOR.CO)
DKK1.04
-0.01 (-0.48%)
DK CPH Healthcare Medical - Diagnostics & Research
Address
Tuborg Havnevej 15, st. 2900
Hellerup, DK
Hellerup, DK
CEO
Carsten Buhl
Website
bioporto.com
IPO
2000-01-13
ISIN DK0011048619
Also trades on
NASDAQ Copenhagen · BIOPOR.CO (DKK)
Other OTC · THOXF (USD)
Description
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
DKK1.04
-0.01 (-0.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
475.7K
Beta
1.38
Float Shares
458.86M
Free Float %
92.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.02% | +14.78% | +35.80% | +50.86% | +25.71% | +26.92% | -5.71% | -12.58% | -62.50% | -70.99% | -93.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.04
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.64
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+11.2% ★ Q4'25: +47.2% (vs Q4'24)
-
EPS growth Medical - Diagnostics & Research: +30.8%+11.8% Q4'25: +35.9% (vs Q4'24)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-197.3% Q4'25: -123.1% (vs Q4'24)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-213.7% Q4'25: -120.4% (vs Q4'24)
-
ROIC Medical - Diagnostics & Research: +5.2%-550.6% Q4'25: -355.4% (vs Q4'24)
-
Share dilution Medical - Diagnostics & Research: 0.0%+32.5% Q4'25: +15.2% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.09× Q4'25: -0.14× (vs Q4'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.02M
est: 30.17M (-13.8%)
|
26.62M
est: 28.53M (-6.7%)
|
23.20M
est: 24.34M (-4.7%)
|
24.25M
est: 23.95M (+1.3%)
|
28.97M
est: 25.40M (+14.1%)
|
30.96M
est: 31.10M (-0.5%)
|
36.24M
est: 40.00M (-9.4%)
|
40.29M
est: 52.25M (-22.9%)
|
42.00M
42.00M – 42.00M
-19.6% YoY
|
60.00M
60.00M – 60.00M
+42.9% YoY
|
142.00M
142.00M – 142.00M
+136.7% YoY
|
| EBITDA |
-40.96M
est: -30.17M (-35.8%)
|
-70.94M
est: -28.53M (-148.6%)
|
-62.00M
est: -24.34M (-154.7%)
|
-58.47M
est: -23.95M (-144.1%)
|
-76.49M
est: -25.40M (-201.2%)
|
-57.89M
est: -31.10M (-86.1%)
|
-70.53M
est: -40.00M (-76.3%)
|
-83.59M
est: -52.25M (-60.0%)
|
-42.00M
-42.00M – -42.00M
+19.6% YoY
|
-60.00M
-60.00M – -60.00M
-42.9% YoY
|
-142.00M
-142.00M – -142.00M
-136.7% YoY
|
| EBIT |
-41.58M
est: -30.17M (-37.8%)
|
-73.80M
est: -28.53M (-158.6%)
|
-65.99M
est: -24.34M (-171.1%)
|
-62.93M
est: -23.95M (-162.8%)
|
-80.46M
est: -25.40M (-216.8%)
|
-60.64M
est: -31.10M (-95.0%)
|
-72.91M
est: -40.00M (-82.3%)
|
-86.09M
est: -52.25M (-64.8%)
|
-42.00M
-42.00M – -42.00M
+19.6% YoY
|
-60.00M
-60.00M – -60.00M
-42.9% YoY
|
-142.00M
-142.00M – -142.00M
-136.7% YoY
|
| Net Income |
-38.05M
est: -63.11M (+39.7%)
|
-69.64M
est: -116.00M (+40.0%)
|
-61.56M
est: -122.93M (+49.9%)
|
-57.11M
est: -81.95M (+30.3%)
|
-75.92M
est: -89.76M (+15.4%)
|
-56.33M
est: -64.92M (+13.2%)
|
-68.24M
est: -96.75M (+29.5%)
|
-82.12M
est: -96.75M (+15.1%)
|
-10.75M
-10.75M – -10.75M
+88.9% YoY
|
-37.63M
-37.63M – -37.63M
-250.0% YoY
|
26.88M
26.88M – 26.88M
+171.4% YoY
|
| SGA |
40.94M
est: 60.03M (-31.8%)
|
67.07M
est: 56.78M (+18.1%)
|
48.80M
est: 48.43M (+0.8%)
|
50.04M
est: 47.65M (+5.0%)
|
63.05M
est: 50.54M (+24.7%)
|
54.90M
est: 61.89M (-11.3%)
|
66.45M
est: 75.49M (-12.0%)
|
64.04M
est: 98.60M (-35.1%)
|
79.26M
79.26M – 79.26M
-19.6% YoY
|
113.23M
113.23M – 113.23M
+42.9% YoY
|
267.98M
267.98M – 267.98M
+136.7% YoY
|
| EPS |
-0.19
est: -0.16 (-22.2%)
|
-0.27
est: -0.29 (+5.6%)
|
-0.29
est: -0.30 (+4.3%)
|
-0.21
est: -0.20 (-4.0%)
|
-0.23
est: -0.22 (-4.0%)
|
-0.16
est: -0.16 (+0.0%)
|
-0.17
est: -0.18 (+5.6%)
|
-0.15
est: -0.18 (+16.7%)
|
-0.02
-0.02 – -0.02
+88.9% YoY
|
-0.07
-0.07 – -0.07
-250.0% YoY
|
0.05
0.05 – 0.05
+171.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-76.03M
OE per share TTM
-0.17
Owner's Yield
-11.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
25.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 3.6K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-17.9K
Shares Outstanding
495.10M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Klaus Juhl Wulff | Executive Vice President & Chief Financial Officer | 5M | male |
| Carsten Buhl | Group Chief Executive Officer | 5M | male |
| Gry Husby Larsen | Executive Vice President & Group Chief Legal Officer | 3M | female |
| Niels Hoey Nielsen | Executive Vice President & Group Chief Financial Officer | 2M | male |
| Jennifer Zonderman | Senior Vice President of Global Marketing & Commercialization | — | female |
| Ursula Klause | Senior Vice President of Global Clinical & Technical Development | — | female |
| Hanne Sogaard | Head of Investor Relations | — | female |
| Jakob Felding | Chief Scientific Officer | — | — |
| Jeffrey Haas | President & Chief Executive Officer of BioPorto Inc. | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOPOR.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
